The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study
文献类型：期刊论文
| 作者 | Xie, Mingying2,3; Li, Na3,4; Xu, Xiaoling1,3; Xu, Yanjun1,3; Li, Hui1,3; Zhu, Liang5 ; Sheng, Jiamin1,3; Zhou, Zichao2,3; Fan, Yun1,3
|
| 刊名 | CANCERS
 |
| 出版日期 | 2022-09-01 |
| 卷号 | 14 |
| 关键词 | liver metastasis non-small cell lung cancer PD-L1 PD-1 PD-L1 inhibitor CD8+T cell |
| DOI | 10.3390/cancers14174333 |
| 通讯作者 | Fan, Yun(fanyun@zjcc.org.cn) |
| 英文摘要 | Simple Summary The liver is a common metastatic site of non-small cell lung cancer (NSCLC) and is associated with a poor prognosis. Immune checkpoint inhibitors (ICIs), represented by programmed death-1 (PD-1)/ programmed death ligand-1 (PD-L1) inhibitors, have significantly improved efficacy in patients with advanced NSCLC, but the efficacy in patients with NSCLC and liver metastases remains controversial. We aimed to evaluate the efficacy of PD-1/PD-L1 inhibitors in patients with NSCLC and liver metastases in the real-world. In this study, we illustrated that PD-1/PD-L1 inhibitors are effective in NSCLC patients with liver metastases but were inferiorly effective in patients without liver metastases. In addition, PD-L1 expression and CD8+ T cell infiltration may be potential biomarkers for PD-1/PD-L1 inhibitor therapy in NSCLC patients with liver metastases. Background: A controversy exists regarding the efficacy of programmed death-1 (PD-1)/ programmed death ligand-1 (PD-L1) inhibitors for patients with non-small cell lung cancer (NSCLC) and liver metastases. Our study retrospectively evaluated the efficacy of PD-1/PD-L1 inhibitors in NSCLC patients with liver metastases. Methods: This retrospective study included 1627 lung cancer patients who received immunotherapy. Among 648 patients who had advanced NSCLC and received PD-1/PD-L1 inhibitors, 61 had liver metastases and 587 did not have. We analyzed patient characteristics, progression-free survival (PFS) and overall survival (OS). An exploratory analysis of biomarkers including CD4, CD8 and CD68 for efficacy in patients with liver metastases was also performed. Results: In liver metastasis patients receiving PD-1/PD-L1 inhibitors, the objective response rate (ORR) was 29.5%, the disease control rate (DCR) was 72.1%, PFS was 6.4 months and OS was 15.2 months, which were all worse than those of patients without liver metastases (ORR: 35.8%; DCR: 81.8%; PFS: 7.9 months, p = 0.001; OS: 20.6 months, p = 0.008). When compared to non-liver lesions, the ORR (26.2 vs. 39.3%) and DCR (75.4 vs. 88.5%) of liver lesions were lower. During the analysis of PD-L1 expression, 27 PD-L1-positive patients had a longer PFS than 21 patients in the negative group (p = 0.012). Being PD-L1 positive was the independent prognostic indicators for PFS (p = 0.006). Additionally, the PD-L1 and CD8 dual-positive group responded favorably to PD-1/PD-L1 inhibitors. Conclusions: PD-1/PD-L1 inhibitors are effective in liver metastasis-NSCLC patients. However, the efficacy is inferior when compared to those of patients without liver metastases. In NSCLC patients with liver metastases, PD-L1 expression and CD8+ T cell infiltration can predict the response of PD-1/PD-L1-directed immunotherapy. |
| WOS关键词 | IMMUNOTHERAPY EFFICACY ; PREDICT SURVIVAL ; SAFETY |
| 资助项目 | Natural Scientific Foundation of China[81972718] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | MDPI |
| WOS记录号 | WOS:000851026100001 |
| 资助机构 | Natural Scientific Foundation of China |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/128854]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Fan, Yun |
| 作者单位 | 1.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou 310022, Peoples R China 2.Zhejiang Chinese Med Univ, Clin Med Coll 2, Dept Oncol, Hangzhou 310053, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou 310022, Peoples R China 4.Wenzhou Med Univ, Clin Med Coll 1, Dept Oncol, Wenzhou 325000, Peoples R China 5.Zhejiang Canc Hosp, Dept Pathol, Hangzhou 310022, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xie, Mingying,Li, Na,Xu, Xiaoling,et al. The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study[J]. CANCERS,2022,14. |
| APA | Xie, Mingying.,Li, Na.,Xu, Xiaoling.,Xu, Yanjun.,Li, Hui.,...&Fan, Yun.(2022).The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study.CANCERS,14. |
| MLA | Xie, Mingying,et al."The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study".CANCERS 14(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。